Bill restores Medicaid savings but shields orphan drugs from price negotiation
H.R. 5094 — Protect Patients from Costly Care Act · Filed by Chris Pappas (D-NH) · 9 cosponsors · Introduced Sep 2, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill repeals two provisions from a 2024 reconciliation law (Public Law 119–21). First, it undoes changes to Medicaid cost-sharing rules that were tightened in that law, restoring the prior Medicaid cost-sharing framework. Second, it repeals changes to the Medicare Drug Price Negotiation Program that had excluded orphan drugs (rare-disease medications), restoring the prior exclusion. The bill also rescinds appropriations tied to the Medicaid cost-sharing changes.
Why we flagged it
The bill's core mechanism is a two-part repeal: it restores Medicaid cost-sharing protections (a public-benefit move) while simultaneously restoring an orphan-drug pricing exemption (a private-benefit move favoring pharmaceutical manufacturers). The net effect is mixed — one arm helps patients, the other shields drug makers from price negotiation.
What the text implies
- Restoring the orphan-drug exclusion from Medicare negotiation may increase federal spending on rare-disease treatments, as Medicare loses negotiating leverage on a category of high-cost drugs.
- The bill's title ('Protect Patients from Costly Care') emphasizes the Medicaid cost-sharing restoration but does not disclose the orphan-drug exemption restoration, creating a framing asymmetry.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers (orphan-drug producers); specialty pharmaceutical companies